Phaseline

Targets › SLC29A1

SLC29A1 (Equilibrative nucleoside transporter 1): drug programs, companies and trials

4 programs from 4 companies in 4 trials: 2 Phase 2, 1 Phase 4, 1 Phase 1; Genitourinary, Cardiovascular, Neurology; next expected readout Dec 2026.

Uniporter involved in the facilitative transport of nucleosides and nucleobases, and contributes to maintaining their cellular homeostasis. Functions as a Na(+)-independent transporter. (UniProt, Q99808)

Open in Phaseline: the race on SLC29A1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Vastra Gotaland RegionDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 4Takotsubo SyndromeDec 2028
Yunfeng XiaDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2Restless Leg Syndrome Due to UraemiaDec 2026
Stanford UniversityDipyridamole
Equilibrative nucleoside transporter 1 inhibitor; 3',5'-cyclic phosphodiesterase inhibitor
SLC29A1, PDE5A, PDE4A, PDE3A, PDE6HPhase 2HypophosphatemiaMay 2027
University of MiamiAbacavir
Human immunodeficiency virus type 1 reverse transcriptase inhibitor
SLC29A1Phase 1High Grade GliomaApr 2029

Conditions

Hypophosphatemia (1) Takotsubo Syndrome (1) Restless Leg Syndrome Due to Uraemia (1) High Grade Glioma (1)

Modalities

small molecule (4)

Companies

Stanford University (1) Vastra Gotaland Region (1) Yunfeng Xia (1) University of Miami (1)

Related targets

PDE5A (3) PDE4A (3) PDE3A (3) PDE6H (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.